TVRDTvardi Therapeutics, Inc.
TVRD
Tvardi Therapeutics, Inc.302
Mkt Cap
$36.87MVolume
30,781.0052W High
$43.6552W Low
$3.85PE Ratio
-0.40TVRD Fundamentals
Price
$3.87Prev Close
$3.93Open
$4.0350D MA
$19.45Beta
-0.11Avg. Volume
632,047.26EPS (Annual)
-$46.60P/B
1.32Rev/Employee
$713,700.00Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Tvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·2d ago
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat...
Business Wire·2d ago
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations...
PR Newswire·6d ago
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat...
Business Wire·7d ago
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc.. (Tvardi or the Company) (NASDAQ: TVRD). Faruqi & Faruqi is a leading...
Business Wire·14d ago
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat...
Business Wire·16d ago
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. (Tvardi or the Company) (NASDAQ...
Business Wire·20d ago
Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now
Tvardi (TVRD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks·23d ago
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...
PR Newswire·23d ago
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation TVRD
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) resulting from...
Business Wire·27d ago